William Blair Comments on AbbVie's Q3 Earnings (NYSE:ABBV)

Key Points

• William Blair analysts have lowered their Q3 2025 earnings estimate for AbbVie to $3.22 per share from a previous estimate of $3.28, while the consensus full-year estimate remains at $12.31 per share.
• AbbVie's stock received several upgrades from different analysts, with Guggenheim increasing the price target from $216.00 to $227.00 and Daiwa Capital raising their rating to "outperform."
• AbbVie recently declared a quarterly dividend of $1.64 per share, yielding approximately 3.0%, while facing a high payout ratio of 312.38%.

AbbVie Inc. (NYSE:ABBV - Free Report) - Investment analysts at William Blair decreased their Q3 2025 earnings estimates for AbbVie in a report issued on Thursday, September 11th. William Blair analyst M. Phipps now expects that the company will earn $3.22 per share for the quarter, down from their prior estimate of $3.28. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share. William Blair also issued estimates for AbbVie's Q4 2025 earnings at $3.18 EPS, FY2025 earnings at $11.83 EPS, Q1 2026 earnings at $3.06 EPS, Q2 2026 earnings at $3.90 EPS, Q3 2026 earnings at $3.72 EPS, Q4 2026 earnings at $3.74 EPS, FY2026 earnings at $14.42 EPS, FY2028 earnings at $17.50 EPS and FY2029 earnings at $18.38 EPS.

Other equities research analysts also recently issued reports about the company. Daiwa Capital Markets raised AbbVie from a "neutral" rating to an "outperform" rating and set a $214.00 price objective for the company in a report on Thursday, August 7th. Wall Street Zen downgraded AbbVie from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Guggenheim increased their price target on AbbVie from $216.00 to $227.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Daiwa America upgraded shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 7th. Finally, Bank of America lifted their price objective on shares of AbbVie to $204.00 and gave the company a "hold" rating in a research report on Monday, June 9th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $217.10.

AbbVie Price Performance

ABBV stock opened at $218.40 on Monday. The company has a market capitalization of $385.82 billion, a P/E ratio of 104.00, a PEG ratio of 1.40 and a beta of 0.53. AbbVie has a twelve month low of $163.81 and a twelve month high of $221.76. The business has a 50 day simple moving average of $200.25 and a 200-day simple moving average of $194.45. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing analysts' consensus estimates of $3.24 by ($0.27). The firm had revenue of $15.42 billion for the quarter, compared to analysts' expectations of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The firm's quarterly revenue was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.65 earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in shares of AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company's stock worth $32,910,186,000 after purchasing an additional 3,380,842 shares in the last quarter. Geode Capital Management LLC boosted its stake in AbbVie by 2.4% during the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company's stock valued at $7,240,169,000 after buying an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in AbbVie by 6.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company's stock valued at $4,970,848,000 after buying an additional 1,517,222 shares in the last quarter. Norges Bank bought a new position in AbbVie during the second quarter valued at about $4,288,200,000. Finally, Northern Trust Corp boosted its stake in AbbVie by 0.9% during the first quarter. Northern Trust Corp now owns 22,013,920 shares of the company's stock valued at $4,612,357,000 after buying an additional 189,294 shares in the last quarter. Institutional investors own 70.23% of the company's stock.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 13,295 shares of AbbVie stock in a transaction on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the completion of the transaction, the executive vice president owned 58,247 shares of the company's stock, valued at $11,562,611.97. The trade was a 18.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of AbbVie stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the transaction, the executive vice president directly owned 177,292 shares of the company's stock, valued at $35,178,278.64. This trade represents a 19.29% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.08% of the company's stock.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 14th. Stockholders of record on Wednesday, October 15th will be paid a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Wednesday, October 15th. AbbVie's payout ratio is 312.38%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.